280 pages | 8 Color Illus. | 30 B/W Illus.
Why a new book on angiogenesis and why now? For the first time concepts proposed over 30 years ago have found clinical validation. In the last two years the first antiangiogenic agents have been approved by the FDA for the treatment of cancer and age-related macular degeneration. Not surprisingly, this clinical success has raised a new set of basic and clinical questions that need to be addressed.
Angiogenesis: From Basic Science to Clinical Applications presents the latest advances in basic science and reviews the status of the clinical applications of angiogenic growth factors and inhibitors. It explores current molecular and genetic findings on the regulation of angiogenesis, discusses the results of clinical trials and identifies the pathological conditions that are most likely to benefit from such treatments.
Edited by a leading researcher in the field, the book includes contributions from multiple experts in their respective disciplines, supplemented by illustrations and photographs. A unique combination of information on basic science and clinical trials research, this book is truly a state-of-the-art review of the state of the science.
“… is a thorough overview of the basic science of the field, with n appropriate focus on VEGF biology. … the book includes several chapters on the role of VEGF in processes other than angiogenesis, including the effects of VEGF on the nervous system. … The strength of the book lies in the expertise and insights of the contributors, who have all made important contributions to the field, including work on the cloning and characterization of numerous angiogenic mediators. The chapters are brief and include clear, easily comprehensible figures that would make excellent slides for lecturers on the basic biology of angiogenesis. … is a outstanding overview of the topic in general and of VEGF biology in particular. …”
—Lee M. Ellis, University of Texas, Anderson Cancer Center, Houston, in The New England Journal of Medicine, Vol. 356, No. 21, pp. 2226-2227, May 2007
"A unique combination of information on basic science and clinical trials research, this book is truly a state-of-the-art review of the state of the science."
– In Anticancer Research, September-October 2007, Vol. 27, No. 5A
Vascular Endothelial Growth Factor: Pathophysiology and Clinical Implications, N. Ferrara
Signal Transduction of VEGF Receptors toward Angiogenesis, M. Shibuya
Growth Factors and Lymphangiogenesis, P.I. Haiko, M.J. Karkkainen, M.G. Achen, S.A. Stacker, and K. Alitalo
Notch and Vascular Development, C.J. Shawber and J. Kitajewski
Neural Guidance Molecules in Vascular Development, L. Yuan, P. Corvol, and A. Eichmann
Neuropilins, Receptors for the VEGF and Semaphorin Families, Link Angiogenesis and Axon Guidance, P. Kurschat, D. Bielenberg, and M. Klagsbrun
Non-Angiogenic Functions of VEGF, J.J. Haigh, C. Ruiz de Almodovar, M. Schneider, and P. Carmeliet
Contribution of Pro-Angiogenic Hematopoietic Cells to Vascularization of Tumor and Ischemic Tissue, S. Rafii, D. Lyden, D. Jin, and A. Hooper
Selected Antiangiogenic Drugs as Potentially Effective Universal Chemosensitizers, R.S. Kerbel, F. Bertolini, S. Man, D.J. Hicklin, U. Emmenegger, and Y. Shaked
Using an Anti-VEGF Monoclonal Antibody to Treat Cancer, Z.A. Wainberg and F. Kabbinavar
Ocular Neovascularization, P.A. Campochiaro
Targeting VEGF for Neovascular Age-Related Macular Degeneration and Macular Edema, P.J. Rosenfeld and A.E. Fung
Therapeutic Angiogenesis for Cardiovascular Disease, R. Khurana and M. Simons